Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
4
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose A soft tissue sarcoma (STS) is a rare type of cancer, accounting for 1% of adult solid cancers. The aim of the present study is to determine the incidence of localized and advanced STS in Korean patients, their treatment patterns, and the survival of patients by disease status. Materials and Methods The STS patient cohort was defined using National Health Insurance Service medical data from 2002 to 2015. Incidence, distribution, anatomical location of tumors, survival rates (Kaplan-Meyer survival function) and treatment patterns were analyzed by applying different algorithms to the STS cohort containing localized and advanced STS cases. Results A total of 7,813 patients were diagnosed with STS from 2007 to 2014, 4,307 were localized STS and 3,506 advanced STS cases. The total incidence of STS was 2.49 per 100,000 person- years: 1.37 per 100,000 person-years for localized STS and 1.12 per 100,000 personyears for advanced STS. The 5-year survival rate after diagnosis was 56.4% for all STS, 82.4% for localized, and 27.2% for advanced STS. Half of the advanced STS patients (49.98%) received anthracycline-containing chemotherapy as initial treatment after diagnosis. Conclusion This study provides insights into localized and advanced STS epidemiology, treatment patterns and outcomes in Korea, which could be used as fundamental data in improving clinical outcomes of STS patients in the future.
Abstract
Purpose A soft tissue sarcoma (STS) is a rare type of cancer, accounting for 1% of adult solid cancers. The aim of the present study is to determine the incidence of localized and advanced STS in Korean patients, their treatment patterns, and the survival of patients by disease status. Materials and Methods The STS patient cohort was defined using National Health Insurance Service medical data from 2002 to 2015. Incidence, distribution, anatomical location of tumors, survival rates (Kaplan-Meyer survival function) and treatment patterns were analyzed by applying different algorithms to the STS cohort containing localized and advanced STS cases. Results A total of 7,813 patients were diagnosed with STS from 2007 to 2014, 4,307 were localized STS and 3,506 advanced STS cases. The total incidence of STS was 2.49 per 100,000 person- years: 1.37 per 100,000 person-years for localized STS and 1.12 per 100,000 personyears for advanced STS. The 5-year survival rate after diagnosis was 56.4% for all STS, 82.4% for localized, and 27.2% for advanced STS. Half of the advanced STS patients (49.98%) received anthracycline-containing chemotherapy as initial treatment after diagnosis. Conclusion This study provides insights into localized and advanced STS epidemiology, treatment patterns and outcomes in Korea, which could be used as fundamental data in improving clinical outcomes of STS patients in the future.
참고문헌 (32)
- Wibmer C, "Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review", Ann Oncol, 21, pp.1106~1111 (2010)
- Burningham Z, "The epidemiology of sarcoma", Clin Sarcoma Res, 2, pp.14~ (2012)
- Casali PG, "Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup", Ann Oncol, 21(Suppl 5), pp.v198~v203 (2010)
- Schoffski P, "Soft tissue sarcoma : an update on systemic treatment options for patients with advanced disease", Oncol Res Treat, 37, pp.355~362 (2014)
- Siegel RL, "Cancer statistics, 2016", CA Cancer J Clin, 66, pp.7~30 (2016)
- Stiller CA, "Descriptive epidemiology of sarcomas in Europe : report from the RARECARE project", Eur J Cancer, 49, pp.684~695 (2013)
- "Estimates of future population 2010-2060" (2011)[URL]
- 강승철, "Incidence and Treatment Pattern of Extremity Soft Tissue Sarcoma in Korea, 2009-2011: A Nationwide Study Based on the Health Insurance Review and Assessment Service Database", Cancer Research and Treatment, 47(4), pp.575~582 (2015), 대한암학회[DOI]
- Fletcher CD, "World Health Organization classification of tumours pathology and genetics of tumours of soft tissue and bone" (2002), IARC Press
- Corless CL, "PDGFRA mutations in gastrointestinal stromal tumors : frequency, spectrum and in vitro sensitivity to imatinib", J Clin Oncol, 23, pp.5357~5364 (2005)
- Italiano A, "Trends in survival for patients with metastatic soft-tissue sarcoma", Cancer, 117, pp.1049~1054 (2011)
- Sheng JY, "Systemic therapy for advanced soft tissue sarcoma", Surg Clin North Am, 96, pp.1141~1156 (2016)
- Krikelis D, "Role of chemotherapy in the management of soft tissue sarcomas", Expert Rev Anticancer Ther, 10, pp.249~260 (2010)
- Seong SC, "Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
- Ogura K, "Statistics of soft-tissue sarcoma in Japan : report from the Bone and Soft Tissue Tumor Registry in Japan", J Orthop Sci, 22, pp.755~764 (2017)
- "SEER cancer statistics review, 1975-2008" (2011)[URL]
- Ray-Coquard I, "Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma(STS)", BMC Cancer, 17, pp.111~ (2017)
- Maretty-Nielsen K, "Prevalence and prognostic impact of comorbidity in soft tissue sarcoma : a population-based cohort study", Acta Oncol, 53, pp.1188~1196 (2014)
- Toro JR, "Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001 : an analysis of 26, 758 cases", Int J Cancer, 119, pp.2922~2930 (2006)
- Bhatt N, "Epidemiological study of soft-tissue sarcomas in Ireland", Cancer Med, 5, pp.129~135 (2016)
- Francis M, "Bone and soft tissue sarcomas: UK incidence and survival: 1996 to 2010" (2013), National Cancer Intelligence Network
- Gustafson P., "Soft tissue sarcoma. Epidemiology and prognosis in 508 patients", Acta Orthop Scand Suppl, 259, pp.1~31 (1994)
- Yang L, "An analysis of incidence trends and characteristics of soft tissue sarcoma in Beijing, 1999-2013", Zhonghua Zhong Liu Za Zhi, 39, pp.471~476 (2017)
- Forman D, "Cancer incidence in five continents. Vol. X" (2014), International Agency for Research on Cancer
- "Surveillance, Epidemiology, and End Results Program" (2016)[URL]
- Mytelka DS, "Advanced soft tissue sarcoma:systemic treatment patterns and survival in Germany", Value Health, 19, pp.A76~ (2016)
- Mytelka DS, "Real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma receiving systemic therapy in the United Kingdom", Value Health, 19, pp.A751~ (2016)
- Bae S, "Patterns of care for patients with advanced soft tissue sarcoma : experience from Australian sarcoma services", Clin Sarcoma Res, 6, pp.11~ (2016)
- Judson I, "Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma : a randomised controlled phase 3 trial", Lancet Oncol, 15, pp.415~423 (2014)
- Tap WD, "Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma : an open-label phase 1b and randomised phase 2 trial", Lancet, 388, pp.488~497 (2016)
- Hoang HL, "Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma", Int J Surg Oncol, 2014, pp.919323~ (2014)
- Potter DA, "Patterns of recurrence in patients with high-grade softtissue sarcomas", J Clin Oncol, 3, pp.353~366 (1985)